CN105816566A - Traditional Chinese medicine formula used for multiple myeloma patients and preparation method thereof - Google Patents
Traditional Chinese medicine formula used for multiple myeloma patients and preparation method thereof Download PDFInfo
- Publication number
- CN105816566A CN105816566A CN201610308825.9A CN201610308825A CN105816566A CN 105816566 A CN105816566 A CN 105816566A CN 201610308825 A CN201610308825 A CN 201610308825A CN 105816566 A CN105816566 A CN 105816566A
- Authority
- CN
- China
- Prior art keywords
- multiple myeloma
- radix
- chinese medicine
- myeloma patients
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims abstract description 34
- 208000034578 Multiple myelomas Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000003814 drug Substances 0.000 title abstract description 23
- 241000255791 Bombyx Species 0.000 claims abstract description 7
- 241000756943 Codonopsis Species 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims abstract description 7
- 210000000582 semen Anatomy 0.000 claims abstract description 6
- 239000002131 composite material Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 11
- 241001057584 Myrrha Species 0.000 claims description 7
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 6
- 241000180649 Panax notoginseng Species 0.000 claims description 6
- 241000237636 Pheretima Species 0.000 claims description 6
- 241000411851 herbal medicine Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 abstract description 13
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 10
- 229960001467 bortezomib Drugs 0.000 abstract description 9
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 abstract description 9
- 238000002512 chemotherapy Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine formula used for multiple myeloma patients, in particular to a traditional Chinese medicine formula used for preventing and treating peripheral neuropathy, caused by bortezomib, of the multiple myeloma patients. The formula takes qi nourishing, kidney tonifying and blood circulation promoting as treatment principles, a Chinese medicine compound is self made and mainly comprises radix astragali and radix codonopsis which are used for nourishing qi and strengthening the body resistance, carapax trionycis, prepared rehmannia root, semen cuscutae, cornus officinalis and fructus rubi which are used for tonifying kidney and replenishing essence, rhizoma chuanxiong, red peony root and myrrh which are used for promoting blood circulation and dredging collaterals, earthworm and bombyx batryticatus which are used for dispelling wind and dredging collaterals, and bidentate achyranthes root used for restoring normal coordination between heart and kidney and ensuring proper downward flow of the blood. The whole formula can be used for nourishing congenitally deficiency, making vital essence sufficient and removing pathogenic factors. By activating blood circulation to remove stasis and dispelling wind and dredging collaterals, blood stasis caused by aeipathia is removed, collaterals are dredged, and pathogenic factors are easy to remove. A project team finds through early research that the self-made qi-nourishing kidney-tonifying and blood-circulation-promoting Chinese medicine compound can improve the treatment effect and meanwhile relieve side effects of chemotherapy.
Description
Technical field
The present invention relates to a kind of Chinese medicine formula for multiple myeloma patients, particularly relate to prevent and treat the Chinese medicine formula of the multiple myeloma patients peripheral neuropathy that bortezomib causes.
Background technology
Multiple myeloma (MM) is a kind of Malignancy originating from B cell system, accounts for the 20% of Malignancy.The multiple middle-aged and elderly people of being born in of this disease, the median age is 57 years old.Its clinical manifestation has the generation of monoclonal immunoglobulin (M albumen), and osteolytic is damaged, anemia, repeated infection and renal failure etc..Chemotherapy is the basic therapy of this disease, and traditional chemotherapy regimen application complete remission rate remains in about 5%, median survival interval only 33 months, and the patient of 80% is dead in 5 years, and the MM patient of Survival for 10 Years is less than 5%.
Bortezomib is a kind of new drug for MM patient, and this is a kind of proteasome inhibitor with unique effect.Bringing important breakthrough for MM treatment, complete remission rate reaches 30-60%, and total effective rate is more than 80%.Along with extensively application and the further investigation of this medicine, its poisonous side effect of medicine is the most increasingly paid close attention to by people, and especially this drug-induced peripheral neuropathy has had a strong impact on the quality of life of MM patient.
Peripheral neuropathy (PeripheralNeuropathy, PN) is the untoward reaction that bortezomib is the most relatively common, it will usually cause DM or treatment to terminate.Sensualness PN incidence rate is higher than mobility PN, and it is main for showing as Progressive symmetric erythrokeratodermia symmetry distal limbs sensory disturbance, numb including finger tip, paresthesia of skin, sense of the sole allergy, limb adynamia and burn feeling and pain etc..Peripheral neuropathy, clinically in addition to common manifestation, it may also occur that based on Progressive symmetric erythrokeratodermia, symmetry distal limbs sensation, the peripheral neuropathy of the dyskinesia, may result in paralysis time serious.Document report BiPN incidence rate reaches 35-66.7%, typically occurs about applying 2 courses for the treatment of, and little patient is resistant to 4 courses for the treatment of of scheme chemotherapy Han bortezomib.Though adjusting dosage and cycle, still having the patient of 6-8% because of BiPN therapy discontinued, after drug withdrawal, major part patient's acroanesthesia, pain symptom gradually alleviate, and still have some patients irreversibility nervous lesion occur.BiPN therapeutic effect to MM to a certain extent brings adverse effect, and has had a strong impact on the quality of life of patient, and for this toxic and side effects, doctor trained in Western medicine is at present without particularly effective prevention and treatment means, and Chinese medicine is expected to search out new breakthrough mouth in this respect.
The traditional Chinese medical science understanding to multiple myeloma, ancient Chinese medicine is without independence " multiple myeloma " name of disease, and this disease sporadically appears in the disease such as " lumbago ", " rheumatism involving the bone ", " osteomyelitis ", " asthenia "." General Treatise on the Cause and Symptoms of Diseases asthenia thigh pivot pain wait " carries: " impairment caused by overstrain vim and vigour, skin natural fibre line of meat void dredges, and by air-cooled thus also.Kidney main waist foot, suffers from a deficiency of the kidney weak, then ailment said due to cold or exposure is taken advantage of, and air-cooled visitor is between thigh pivot, therefore pain is also ".The kidney generating marrow and dominating bone, multiple myeloma is more common in middle-aged and elderly people, and deficiency of kidney-essence, muscles and bones is lost and supported, therefore osteodynia, fracture, lumbago shape easily occurs.It is for suffering from a deficiency of the kidney, and due to vital essence virtual loss, governor vessel is deficient；The heresy of wind and cold noxious dampness or the heresy invasion and attack body of rheumatism pyretic toxicity, cause QI-blood circulation not smooth, and blood stasis resistance network is mark.Control invigorate blood circulation based on vital energy benefiting and the kidney invigorating, removing obstruction in the collateral to relieve pain.
Bortezomib for treating multiple myeloma is evident in efficacy, but this drug-induced peripheral neuropathy becomes global problem, at present without particularly effective medicine and Therapeutic Method.
Summary of the invention
The deficiency existed for prior art, it is an object of the present invention to provide the Chinese medicine formula playing the multiple myeloma patients peripheral neuropathy that preventing and treating bortezomib causes, and its second purpose is to decoct suitably, maximum can play drug effect.
In order to realize above-mentioned first purpose, present invention employs following technical scheme: a kind of herbal composite for multiple myeloma patients, compositions consists of Radix Astragali 30-50 part, Radix Codonopsis 20-30 part, Radix Rehmanniae Preparata 20-30 part, Fructus Corni 15-20 part, Fructus Psoraleae 10-15 part, Semen Cuscutae 10-15 part, Radix Angelicae Sinensis 10-15 part, Rhizoma Chuanxiong 8-15 part, Fructus Rubi 15-20 part, Radix Paeoniae Rubra 8-15 part, Pheretima 8-15 part, Bombyx Batryticatus 8-15 part, Radix Achyranthis Bidentatae 8-15 part.
Preferably: outside herbal composite, also include following component: halfhour Carapax Trionycis 20-30 part of being decocted first.
In order to realize above-mentioned second purpose, present invention employs following technical scheme:
A kind of herbal composite for multiple myeloma patients, the method comprises the following steps:
After above herbal composite is wrapped the 1h that is soaked in water, pouring halfhour Carapax Trionycis 20-30 part of being decocted first into, decoct 2 times, add 8 times amount soak by water 1.5h for the first time, second time adds 6 times amount soak by water 1h, merges twice decoction liquor and filters, filtrate；Merging twice decoction liquor to filter, filtrate adds Radix Notoginseng 8-15 part of levigation, Myrrha 8-15 part.
Compared with prior art, the invention has the beneficial effects as follows: this formula with " vital energy benefiting and the kidney invigorating is invigorated blood circulation " as Therapeutic Principle, from intending Chinese medicine compound, key agents has the Radix Astragali, Radix Codonopsis QI invigorating righting, Carapax Trionycis, Radix Rehmanniae Preparata, Semen Cuscutae, Fructus Corni, Fructus Rubi kidney tonifying, essence replenishing, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Myrrha promoting blood circulation to remove obstruction in the collateral, Pheretima, Bombyx Batryticatus dispelling wind dredging collateral, Radix Achyranthis Bidentatae restoring normal coordination between the heart and kidney, conducting blood to flow downwards.Full side can take a tonic or nourishing food to build up one's health congenital, and vital essence is sufficient and heresy can not be deposited, and stays the stasis of blood by blood circulation promoting and blood stasis dispelling, dispelling wind dredging collateral because of prolonged illness to dispel, and venation is logical and heresy is easily gone.Project team is found by early-stage Study, can improve curative effect from intending " vital energy benefiting and the kidney invigorating is invigorated blood circulation " Chinese medicine compound combined chemotherapy, alleviate chemotherapy side effect simultaneously.
Detailed description of the invention
The following specific embodiments of the present invention is to make a detailed explanation.
Embodiment 1
A kind of herbal composite for multiple myeloma patients, compositions consists of Radix Astragali 30g, Radix Codonopsis 20g, Radix Rehmanniae Preparata 20g, Fructus Corni 15g, Fructus Psoraleae 10g, Semen Cuscutae 10g, Radix Angelicae Sinensis 10g, Rhizoma Chuanxiong 8g, Fructus Rubi 15g, Radix Paeoniae Rubra 8g, Pheretima 8g, Bombyx Batryticatus 8g, Radix Achyranthis Bidentatae 8g.
A kind of herbal composite for multiple myeloma patients, also includes following component: be decocted first halfhour Carapax Trionycis 20g outside herbal composite.
The preparation method of a kind of Chinese herbal medicine for multiple myeloma patients, the method comprises the following steps:
After above herbal composite is wrapped the 1h that is soaked in water, pouring the halfhour Carapax Trionycis 20g that is decocted first into, decoct 2 times, add 8 times amount soak by water 1.5h for the first time, second time adds 6 times amount soak by water 1h, merges twice decoction liquor and filters, filtrate；Merging twice decoction liquor to filter, filtrate adds the Radix Notoginseng 8g of levigation, Myrrha 8g.
Embodiment 2
A kind of herbal composite for multiple myeloma patients, compositions consists of Radix Astragali 40g, Radix Codonopsis 25g, Radix Rehmanniae Preparata 25g, Fructus Corni 18g, Fructus Psoraleae 12g, Semen Cuscutae 12g, Radix Angelicae Sinensis 12g, Rhizoma Chuanxiong 11g, Fructus Rubi 18g, Radix Paeoniae Rubra 11g, Pheretima 11g, Bombyx Batryticatus 11g, Radix Achyranthis Bidentatae 11g.
A kind of herbal composite for multiple myeloma patients, also includes following component: be decocted first halfhour Carapax Trionycis 25g outside herbal composite.
The preparation method of a kind of Chinese herbal medicine for multiple myeloma patients, the method comprises the following steps:
After above herbal composite is wrapped the 1h that is soaked in water, pouring the halfhour Carapax Trionycis 20-30g that is decocted first into, decoct 2 times, add 8 times amount soak by water 1.5h for the first time, second time adds 6 times amount soak by water 1h, merges twice decoction liquor and filters, filtrate；Merging twice decoction liquor to filter, filtrate adds the Radix Notoginseng 12g of levigation, Myrrha 12g.
Embodiment 3
A kind of herbal composite for multiple myeloma patients, compositions consists of Radix Astragali 50g, Radix Codonopsis 30g, Radix Rehmanniae Preparata 30g, Fructus Corni 20g, Fructus Psoraleae 15g, Semen Cuscutae 15g, Radix Angelicae Sinensis 15g, Rhizoma Chuanxiong 15g Fructus Rubi 20g Radix Paeoniae Rubra 15g Pheretima 15g Bombyx Batryticatus 15g Radix Achyranthis Bidentatae 15g
Following component is also included: be decocted first halfhour Carapax Trionycis 30g outside herbal composite.
The preparation method of a kind of Chinese herbal medicine for multiple myeloma patients, the method comprises the following steps:
After above herbal composite is wrapped the 1h that is soaked in water, pouring the halfhour Carapax Trionycis 30g that is decocted first into, decoct 2 times, add 8 times amount soak by water 1.5h for the first time, second time adds 6 times amount soak by water 1h, merges twice decoction liquor and filters, filtrate；Merging twice decoction liquor to filter, filtrate adds the Radix Notoginseng 15g of levigation, Myrrha 15g.
Above manufacturing process is the amount of a day, and filtrate obtains 500-600g medicine soup after adding the Radix Notoginseng 15g of levigation, Myrrha 15g, and every day, half an hour took after the meal, totally 3 times.
Patient is using after this prescription, clinical observation on the therapeutic effect:
By investigation and comparison, from a kind of Chinese herbal medicine formula for multiple myeloma patients intended, Chinese medicine compound can reduce the peripheral neuropathy that bortezomib causes, and incidence rate is 8.7%, and substantially less than the 63.5% of matched group, and occurrence degree substantially alleviates.Significantly improve patients ' life quality, and improve patient's tolerance to chemotherapy.
After taking treatment 6 months with the application prescription, by reducing the hypercoagulability of patient, improving chemosensitivity degree, thus improve therapeutic effect, Chinese medicine combined chemotherapy total effective rate reaches 86.5%, hence it is evident that higher than chemotherapy group.
We's medicine is by alleviating MM patient's hypercoagulability, improve the sensitivity of chemotherapy, simultaneously by improving kidney and each organ circulation of whole body, can alleviate multiple myeloma patients renal function injury, Blood-hyperviscosity causes the complication such as important organ hypoxic-ischemic even thrombosis, can also be used together with bortezomib, play the effect of collaborative superposition.
Claims (3)
1. the herbal composite for multiple myeloma patients, it is characterised in that compositions consists of Radix Astragali 30-50 part, Radix Codonopsis 20-30 part, Radix Rehmanniae Preparata 20-30 part, Fructus Corni 15-20 part, Fructus Psoraleae 10-15 part, Semen Cuscutae 10-15 part, Radix Angelicae Sinensis 10-15 part, Rhizoma Chuanxiong 8-15 part, Fructus Rubi 15-20 part, Radix Paeoniae Rubra 8-15 part, Pheretima 8-15 part, Bombyx Batryticatus 8-15 part, Radix Achyranthis Bidentatae 8-15 part.
A kind of herbal composite for multiple myeloma patients the most according to claim 1, it is characterised in that also include following component outside herbal composite: halfhour Carapax Trionycis 20-30 part of being decocted first.
3. the preparation method of a kind of Chinese herbal medicine for multiple myeloma patients described in claim 1 or 2, it is characterised in that the method comprises the following steps:
After above herbal composite is wrapped the 1h that is soaked in water, pouring halfhour Carapax Trionycis 20-30 part of being decocted first into, decoct 2 times, add 8 times amount soak by water 1.5h for the first time, second time adds 6 times amount soak by water 1h, merges twice decoction liquor and filters, filtrate；Merging twice decoction liquor to filter, filtrate adds Radix Notoginseng 8-15 part of levigation, Myrrha 8-15 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610308825.9A CN105816566A (en) | 2016-05-11 | 2016-05-11 | Traditional Chinese medicine formula used for multiple myeloma patients and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610308825.9A CN105816566A (en) | 2016-05-11 | 2016-05-11 | Traditional Chinese medicine formula used for multiple myeloma patients and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105816566A true CN105816566A (en) | 2016-08-03 |
Family
ID=56528679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610308825.9A Pending CN105816566A (en) | 2016-05-11 | 2016-05-11 | Traditional Chinese medicine formula used for multiple myeloma patients and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105816566A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634219A (en) * | 2004-04-10 | 2005-07-06 | 张彦君 | Orally administered Chinese medicinal powder and ointment for treating femoral head necroses and its preparation process |
| CN1911340A (en) * | 2006-08-04 | 2007-02-14 | 王跃普 | Traditional Chinese medicine for treating cancer |
| CN102284010A (en) * | 2011-07-28 | 2011-12-21 | 北京中科血康血液病医学研究院 | Composition for treating leukemia, myeloma multiplex and myelodysplastic syndrome |
| CN104127637A (en) * | 2014-08-14 | 2014-11-05 | 刘尚勤 | Traditional Chinese medicine formula for maintenance treatment of multiple myeloma |
| CN102872336B (en) * | 2012-08-29 | 2014-11-05 | 庄步玺 | Traditional Chinese medicine for treating multiple myeloma |
| CN105079149A (en) * | 2015-09-01 | 2015-11-25 | 周亚伟 | Application of Xiaojin Pills in preparation of medicine treating multiple myeloma |
-
2016
- 2016-05-11 CN CN201610308825.9A patent/CN105816566A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634219A (en) * | 2004-04-10 | 2005-07-06 | 张彦君 | Orally administered Chinese medicinal powder and ointment for treating femoral head necroses and its preparation process |
| CN1911340A (en) * | 2006-08-04 | 2007-02-14 | 王跃普 | Traditional Chinese medicine for treating cancer |
| CN102284010A (en) * | 2011-07-28 | 2011-12-21 | 北京中科血康血液病医学研究院 | Composition for treating leukemia, myeloma multiplex and myelodysplastic syndrome |
| CN102872336B (en) * | 2012-08-29 | 2014-11-05 | 庄步玺 | Traditional Chinese medicine for treating multiple myeloma |
| CN104127637A (en) * | 2014-08-14 | 2014-11-05 | 刘尚勤 | Traditional Chinese medicine formula for maintenance treatment of multiple myeloma |
| CN105079149A (en) * | 2015-09-01 | 2015-11-25 | 周亚伟 | Application of Xiaojin Pills in preparation of medicine treating multiple myeloma |
Non-Patent Citations (1)
| Title |
|---|
| 南京药学院主编: "《药剂学》", 31 March 1978, 北京：人民卫生出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463404B (en) | Traditional Chinese medicine composition for treating liver and kidney yin deficiency | |
| CN103007191A (en) | Chinese medicinal composition for treating jaundice | |
| CN1091609C (en) | Tincture for treating rheumatoid arthritis and its preparing process | |
| CN103505714B (en) | Traditional Chinese medicine for treating palpitation with syndrome of heart-blood insufficiency | |
| CN104606470A (en) | Traditional Chinese medicine composition for treating endocrine dyscrasia | |
| CN104013910A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN103393860B (en) | Traditional Chinese medicine composition for treating hyperactivity of liver-yang | |
| CN103041200B (en) | Traditional Chinese medicine composition for treating cerebral hemorrhage | |
| CN103721082B (en) | A kind of Chinese medicine composition of cure scapulohumeral periarthritis | |
| CN103041271B (en) | Traditional Chinese medicine composition for treating emphysema | |
| CN102512645B (en) | Traditional Chinese medicine composition for treating lumbago due to cold dampness | |
| CN101040960A (en) | Medicine for treating hepatitis | |
| CN103479835A (en) | Traditional Chinese medicine for treating liver cirrhosis | |
| CN102988860B (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN102988632B (en) | Chinese medicinal composition for treating oedematous | |
| CN105902872A (en) | Traditional Chinese medicine composition for treating edema | |
| CN102512543B (en) | Chinese medicinal composition for treating rheumatoid arthritis | |
| CN105816566A (en) | Traditional Chinese medicine formula used for multiple myeloma patients and preparation method thereof | |
| CN102058842B (en) | Traditional Chinese medicine composition for treating hemiplegic stroke or premonitory apoplexy | |
| CN105477330A (en) | Traditional Chinese medicine composition for treating arrhythmia | |
| CN102784256B (en) | Chinese medicine composition for treating arthralgia-synadrome | |
| CN102349983A (en) | Traditional Chinese medicine composition for treating ischemic apoplexia | |
| CN106177642A (en) | A kind of endo-medicine treating rheumatoid arthritis and preparation method thereof | |
| CN106256372A (en) | A kind of endo-medicine treating chronic prostatitis and preparation method thereof | |
| CN105920440A (en) | Chinese medicinal composition for treating edema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |